130.39
3.42 (2.69%)
Previous Close | 126.97 |
Open | 128.60 |
Volume | 844,276 |
Avg. Volume (3M) | 1,114,554 |
Market Cap | 16,126,765,056 |
Price / Sales | 11.16 |
Price / Book | 18.77 |
52 Weeks Range | |
Earnings Date | 12 Nov 2024 |
Profit Margin | -21.47% |
Operating Margin (TTM) | -10.62% |
Diluted EPS (TTM) | -2.50 |
Quarterly Revenue Growth (YOY) | 58.10% |
Total Debt/Equity (MRQ) | 52.31% |
Current Ratio (MRQ) | 4.14 |
Operating Cash Flow (TTM) | -56.31 M |
Levered Free Cash Flow (TTM) | -46.68 M |
Return on Assets (TTM) | -14.18% |
Return on Equity (TTM) | -40.78% |
Market Trend
Short Term | Medium Term | ||
Industry | Diagnostics & Research (US) | Bullish | Mixed |
Diagnostics & Research (Global) | Bullish | Mixed | |
Stock | Natera, Inc. | Bullish | Bullish |
Stockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | -5.0 |
Price Volatility | -0.5 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 2.0 |
Average | 0.10 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. |
|
Sector | Healthcare |
Industry | Diagnostics & Research |
Investment Style | Mid Growth |
% Held by Insiders | 3.68% |
% Held by Institutions | 99.07% |
Ownership
Name | Date | Shares Held |
---|---|---|
Farallon Capital Management Llc | 30 Jun 2024 | 4,460,557 |
Rtw Investments, Lp | 30 Jun 2024 | 2,593,323 |
Massachusetts Financial Services Co /Ma/ | 30 Jun 2024 | 2,397,582 |
Duquesne Family Office Llc | 30 Jun 2024 | 1,974,880 |
52 Weeks Range | ||
Price Target Range | ||
High | 150.00 (Canaccord Genuity, 15.04%) | Buy |
150.00 (Leerink Partners, 15.04%) | Buy | |
150.00 (Piper Sandler, 15.04%) | Buy | |
Median | 140.00 (7.37%) | |
Low | 120.00 (Baird, -7.97%) | Buy |
Average | 138.82 (6.47%) | |
Total | 11 Buy | |
Avg. Price @ Call | 119.91 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Bernstein | 30 Oct 2024 | 135.00 (3.54%) | Buy | 126.73 |
Canaccord Genuity | 29 Oct 2024 | 150.00 (15.04%) | Buy | 124.74 |
27 Aug 2024 | 145.00 (11.20%) | Buy | 120.27 | |
Leerink Partners | 17 Oct 2024 | 150.00 (15.04%) | Buy | 122.35 |
Goldman Sachs | 16 Oct 2024 | 140.00 (7.37%) | Buy | 126.77 |
Piper Sandler | 13 Sep 2024 | 150.00 (15.04%) | Buy | 126.51 |
13 Aug 2024 | 150.00 (15.04%) | Buy | 119.02 | |
Morgan Stanley | 13 Aug 2024 | 132.00 (1.23%) | Buy | 119.02 |
BTIG | 09 Aug 2024 | 135.00 (3.54%) | Buy | 114.57 |
Baird | 09 Aug 2024 | 120.00 (-7.97%) | Buy | 114.57 |
Stephens & Co. | 09 Aug 2024 | 125.00 (-4.13%) | Buy | 114.57 |
TD Cowen | 09 Aug 2024 | 145.00 (11.20%) | Buy | 114.57 |
UBS | 09 Aug 2024 | 145.00 (11.20%) | Buy | 114.57 |
Show more |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
BROPHY MICHAEL BURKES | - | 122.14 | -3,858 | -469,204 |
CHAPMAN STEVEN LEONARD | - | 120.71 | -3,960 | -478,012 |
FESKO JOHN | - | 120.71 | -929 | -112,140 |
MOSHKEVICH SOLOMON | - | 120.71 | -1,196 | -144,369 |
RABINOWITZ DANIEL | - | 120.71 | -1,057 | -127,590 |
Aggregate Net Quantity | -11,000 | |||
Aggregate Net Value ($) | -1,331,315 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | 121.32 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
BROPHY MICHAEL BURKES | Officer | 31 Oct 2024 | Automatic sell (-) | 1,866 | 120.96 | 225,711 |
BROPHY MICHAEL BURKES | Officer | 29 Oct 2024 | Automatic sell (-) | 754 | 124.74 | 94,054 |
FESKO JOHN | Officer | 28 Oct 2024 | Automatic sell (-) | 929 | 120.71 | 112,140 |
RABINOWITZ DANIEL | Officer | 28 Oct 2024 | Automatic sell (-) | 1,057 | 120.71 | 127,590 |
CHAPMAN STEVEN LEONARD | Officer | 28 Oct 2024 | Automatic sell (-) | 3,960 | 120.71 | 478,012 |
MOSHKEVICH SOLOMON | Officer | 28 Oct 2024 | Automatic sell (-) | 1,196 | 120.71 | 144,369 |
BROPHY MICHAEL BURKES | Officer | 28 Oct 2024 | Automatic sell (-) | 1,238 | 120.71 | 149,439 |
Date | Type | Details |
---|---|---|
08 Nov 2024 | Announcement | Natera to Participate in Upcoming Investor Conferences |
01 Nov 2024 | Announcement | Natera to Report its Third Quarter 2024 Results on November 12, 2024 |
22 Oct 2024 | Announcement | Natera to Present New Renasight Data at ASN Kidney Week 2024 |
23 Sep 2024 | Announcement | Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase |
16 Sep 2024 | Announcement | Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO |
14 Sep 2024 | Announcement | First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival |
08 Sep 2024 | Announcement | Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival |
28 Aug 2024 | Announcement | Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |